NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $12.72 -0.23 (-1.78%) As of 05/20/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avidity Biosciences Stock (NASDAQ:RNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avidity Biosciences alerts:Sign Up Key Stats Today's Range$12.61▼$13.0150-Day Range$12.32▼$14.8052-Week Range$11.95▼$16.77Volume168,126 shsAverage Volume605,753 shsMarket Capitalization$217.59 millionP/E RatioN/ADividend YieldN/APrice Target$69.42Consensus RatingHold Company Overview Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms. The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study. Preclinical programs include additional neuromuscular indications such as Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy (XLMTM). Avidity’s research efforts focus on optimizing conjugate design, antibody selection, and oligonucleotide chemistries to maximize tissue uptake and therapeutic potency. Avidity Biosciences was founded in 2017 by a team of scientists and entrepreneurs with expertise in antibody engineering, oligonucleotide chemistry and muscle biology. The company went public on the Nasdaq Global Market under the ticker RNA in January 2021. Laurent Fischer, M.D., serves as Chief Executive Officer, drawing on his background in immunology and drug discovery to guide the company’s strategic and clinical initiatives. Avidity maintains research and development operations in the United States and engages in collaborations to expand the reach of its AOC technology. Building on its foundational platform, Avidity continues to advance multiple pipeline candidates through preclinical and clinical stages, while exploring partnership opportunities with biopharmaceutical companies. The company’s long-term objective is to transform the treatment landscape for patients with genetic muscle disorders by delivering precision RNA therapies with improved safety, efficacy and convenience.AI Generated. May Contain Errors. Read More Avidity Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreRNA MarketRank™: Avidity Biosciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 569th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingAvidity Biosciences has received a consensus rating of Hold. The company's average rating score is 2.37, and is based on 1 strong buy rating, 6 buy ratings, 11 hold ratings, and 1 sell rating.Upside PotentialAvidity Biosciences has a consensus price target of $69.42, representing about 445.8% upside from its current price of $12.72.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Avidity Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.30% of the float of Avidity Biosciences has been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 8.71.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 13.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.80 News SentimentAvidity Biosciences has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Avidity Biosciences this week, compared to 4 articles on an average week.MarketBeat Follows3 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.83% of the stock of Avidity Biosciences is held by insiders.Percentage Held by InstitutionsAvidity Biosciences has minimal institutional ownership at this time.Read more about Avidity Biosciences' insider trading history. Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNA Stock News HeadlinesAvidity Biosciences, Inc. (NASDAQ:RNA) Given Average Recommendation of "Hold" by BrokeragesMay 17, 2026 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Downgraded by Wall Street Zen to "Sell"May 16, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 21 at 1:00 AM | Banyan Hill Publishing (Ad)Atrium Therapeutics Reports First Quarter 2026 Financial ResultsMay 14, 2026 | prnewswire.comAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationApril 23, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 20, 2026 | prnewswire.comNovartis Uses US Bond Issue To Expand RNA And Peptide PipelineMarch 19, 2026 | uk.finance.yahoo.comNovartis acquisition spin-off pioneers RNA therapeutics for the heartMarch 19, 2026 | finance.yahoo.comSee More Headlines RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $72.13 at the beginning of 2026. Since then, RNA stock has decreased by 82.4% and is now trading at $12.72. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) released its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.08. The biotechnology company had revenue of $19.64 million for the quarter, compared to analyst estimates of $2 million. Avidity Biosciences had a negative net margin of 3,650.39% and a negative trailing twelve-month return on equity of 44.92%. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $216 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,400,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/14/2026Today5/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNA CIK1599901 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year Founded2013Price Target and Rating Average Price Target for Avidity Biosciences$69.42 High Price Target$96.00 Low Price Target$55.00 Potential Upside/Downside+445.8%Consensus RatingHold Rating Score (0-4)2.37 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$322.30 million Net Margins-3,650.39% Pretax Margin-3,650.39% Return on Equity-44.92% Return on Assets-39.57% Debt Debt-to-Equity RatioN/A Current Ratio9.20 Quick Ratio11.57 Sales & Book Value Annual Sales$36.68 million Price / Sales5.93 Cash FlowN/A Price / Cash FlowN/A Book Value$10.88 per share Price / Book1.17Miscellaneous Outstanding Shares17,106,000Free Float149,208,000Market Cap$217.59 million OptionableOptionable Beta0.93 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:RNA) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
